Nintedanib’s safety and tolerability profile is similar in patients with systemic sclerosis-associated interstitial lung disease and those with idiopathic pulmonary fibrosis, according to a comparison of data from the SENSCIS and INPULSIS trials.
Research shows that patients with psoriatic arthritis gain substantial improvements in both musculoskeletal and skin symptoms with bimekizumab, highlighting the benefits of its ability to neutralize both interleukin-17A and 17F.
Randomized trial findings presented at the EULAR 2019 congress in Madrid, Spain, suggest that pirfenidone does not stabilize or improve lung function in patients with systemic sclerosis-associated interstitial lung disease.
Rheumatoid arthritis patients who achieve low disease activity with tocilizumab and low-dose glucocorticoids should be considered for glucocorticoid tapering, suggests research presented at the EULAR 2019 congress in Madrid, Spain.
Juvenile idiopathic arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapy have similar outcomes regardless of whether they switch to a second agent from the same class or an alternative biologic, research suggests.
Fenebrutinib has shown efficacy for reducing rheumatoid arthritis activity in patients with an inadequate response to either methotrexate or tumor necrosis factor inhibitors, phase II study findings show.
Findings from the phase III FINCH 1 trial suggest that use of the selective Janus kinase 1 inhibitor filgotinib may be beneficial for patients with rheumatoid arthritis and a previous inadequate response to methotrexate.
Patients with rheumatoid arthritis who initially fail to respond to either the Janus kinase inhibitor upadacitinib or the tumor necrosis factor inhibitor adalimumab can benefit from switching to the alternative drug, post-hoc analysis of the SELECT-COMPARE study suggests.
More than a third of patients with giant cell arteritis remission who discontinue tocilizumab treatment after 1 year remain in clinical remission for a further 2 years, suggest follow-up results from the GiACTA trial.
Sustained remission and low disease activity remain uncommon in patients with rheumatoid arthritis receiving anti-tumor necrosis factor therapy but can be predicted by several factors, shows an analysis published in Rheumatology.
Increased atherosclerotic plaque burden, as estimated by carotid ultrasound, is associated with an increased risk for cardiovascular events in patients with psoriatic disease, Canadian researchers report.
Dose reduction of tumor necrosis factor (TNF) inhibitors may be an appropriate strategy for rheumatoid arthritis patients who achieve low disease activity while receiving full doses of the agents, report the authors of a Cochrane systematic review.
Patients with early rheumatoid arthritis who are treated with the interleukin-6 receptor inhibitor tocilizumab experience more pronounced repair of bone erosions than those given adalimumab plus methotrexate, indicate findings from the REBONE study.